Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A porcine model of osteosarcoma.
Saalfrank A, Janssen KP, Ravon M, Flisikowski K, Eser S, Steiger K, Flisikowska T, Müller-Fliedner P, Schulze É, Brönner C, Gnann A, Kappe E, Böhm B, Schade B, Certa U, Saur D, Esposito I, Kind A, Schnieke A. Saalfrank A, et al. Among authors: schulze e. Oncogenesis. 2016 Mar 14;5(3):e210. doi: 10.1038/oncsis.2016.19. Oncogenesis. 2016. PMID: 26974205 Free PMC article.
In Vivo Analysis of Disease-Associated Point Mutations Unveils Profound Differences in mRNA Splicing of Peripherin-2 in Rod and Cone Photoreceptors.
Becirovic E, Böhm S, Nguyen ON, Riedmayr LM, Koch MA, Schulze E, Kohl S, Borsch O, Santos-Ferreira T, Ader M, Michalakis S, Biel M. Becirovic E, et al. Among authors: schulze e. PLoS Genet. 2016 Jan 21;12(1):e1005811. doi: 10.1371/journal.pgen.1005811. eCollection 2016 Jan. PLoS Genet. 2016. PMID: 26796962 Free PMC article.
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R. Burges A, et al. Among authors: schulze e. Clin Cancer Res. 2007 Jul 1;13(13):3899-905. doi: 10.1158/1078-0432.CCR-06-2769. Clin Cancer Res. 2007. PMID: 17606723 Clinical Trial.
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M. Heiss MM, et al. Among authors: schulze e. Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8. Clin Cancer Res. 2014. PMID: 24714773 Clinical Trial.
Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL. Wimberger P, et al. Among authors: schulze e. Ann Oncol. 2012 Aug;23(8):1979-1985. doi: 10.1093/annonc/mds178. Epub 2012 Jun 24. Ann Oncol. 2012. PMID: 22734013 Free PMC article. Clinical Trial.
544 results